Document is current
Any future updates will be listed below
-
Authors
Spanjaart, Anne Mea
Ljungman, Per
Tridello, Gloria
Schwartz, Juana
Martinez-Cibrián, Nuria
Barba, Pere https://orcid.org/0000-0003-1038-5197
Kwon, Mi
Lopez-Corral, Lucia https://orcid.org/0000-0003-1908-5596
Martinez-Lopez, Joaquin https://orcid.org/0000-0001-7908-0063
Ferra, Christelle
Di Blasi, Roberta
Ghesquieres, Hervé
Mutsaers, Pim https://orcid.org/0000-0002-3924-8578
Calkoen, Friso https://orcid.org/0000-0001-9059-0929
Jak, Margot
van Doesum, Jaap https://orcid.org/0000-0003-0214-3219
Vermaat, Joost S. P.
van der Poel, Marjolein
Maertens, Johan https://orcid.org/0000-0003-4257-5980
Gambella, Massimiliano
Metafuni, Elisabetta
Ciceri, Fabio
Saccardi, Riccardo
Nicholson, Emma https://orcid.org/0000-0002-6439-0795
Tholouli, Eleni
Matthew, Collin
Potter, Victoria
Bloor, Adrian
Besley, Caroline
Roddie, Claire
Wilson, Keith https://orcid.org/0000-0002-6327-9366
Nagler, Arnon
Campos, Antonio
Petersen, Soeren Lykke
Folber, Frantisek https://orcid.org/0000-0001-7034-769X
Bader, Peter
Finke, Jurgen https://orcid.org/0000-0002-1799-5927
Kroger, Nicolaus https://orcid.org/0000-0001-5103-9966
Knelange, Nina
de La Camara, Rafael https://orcid.org/0000-0002-8189-5779
Kersten, Marie José https://orcid.org/0000-0002-8904-3802
Mielke, Stephan https://orcid.org/0000-0003-0167-6021
- License Information
-
More Information
Article History
Received: 3 April 2024
Revised: 4 June 2024
Accepted: 2 July 2024
First Online: 23 July 2024
Competing interests
: There is no financial support for this work that could have influenced the outcomes described in the manuscript. However, several authors report a potential conflict of interest, which is described below. PL has received speaker fees for Kite/Gilead and Pfizer, PB received advisory board and consultancy fees from Allogene, Amgen, BMS/Celgene, Kite/Gilead, Incyte, Miltenyi Biomedicine, Novartis, Nektar, Pfizer and Pierre Fabre, JM has received research support from Pfizer and Gilead and has served as a consultant or speaker for Gilead, Pfizer, MSD, Cidara, Mundipharma, F2G, Amplyx, Basilea, Shionoghi, Synexis and Takeda, AB has received fees for conference attendance and advisory boards from Kite/Gilead and consultancy fees from NovartisSLP participated in advisory boards for Novartis, Kite-Gilead and Janssen, MJK reports honoraria from BMS/Celgene, Kite/Gilead, Novartis, and Roche; consulting or advisory roles for BMS/Celgene, Kite Gilead, Miltenyi Biotec, Novartis, Takeda Pharmaceuticals, and Adicet Bio; and research funding from Kite Gilead, all to her institution. RC has received speaker fees for MSD, GSK, Novartis, Pfizer, Gilead and received advisory board and consultancy fees from MSD, Astellas, Roche; SM has received speaker’s fees via his institution from Celgene/BMS, Novartis, Janssen and Pfizer, received travel support and fees via his institution for participation in an expert panel from Kite/Gilead, served on DSMB for Miltenyi and Mendes (via his institution), is the founder of SWECARNET (via his institution) and his spouse is the founder of ScientifyResearch.
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Swedish central Ethical Board (EPM 2020-01731, 2021-04692). All patients gave informed consent to have their data reported to the EBMT registry.
